Cardiovascular Systems, Inc. (NASDAQ:CSII) Files An 8-K Results of Operations and Financial Condition

0

Cardiovascular Systems, Inc. (NASDAQ:CSII) Files An 8-K Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition.

As further discussed in Item 8.01 below, on April 17, 2017,
Cardiovascular Systems, Inc. (the Company) issued a press release
regarding a voluntary recall action, including an expected charge
of $1.5 million to be incurred in the third quarter of fiscal
2017, reflecting its current estimate of the costs associated
with the action. The Company indicated that the recall and
related charge do not have an adverse effect on third quarter
revenue and net loss guidance provided by the Company on January
25, 2017.
Item 8.01. Other Events.
On April 17, 2017, the Company issued a press release announcing
a voluntary recall of its 7-10014 Saline Infusion Pump. A copy of
the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
Number
Description
99.1
Press release dated April 17, 2017


About Cardiovascular Systems, Inc. (NASDAQ:CSII)

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

Cardiovascular Systems, Inc. (NASDAQ:CSII) Recent Trading Information

Cardiovascular Systems, Inc. (NASDAQ:CSII) closed its last trading session up +0.07 at 28.87 with 163,657 shares trading hands.